Bulletin
Investor Alert

New York Markets After Hours

Medicure Inc.

OTC: MCUJF

GO
/marketstate/country/us

Market closed

/zigman2/quotes/204944769/composite

$

0.68

Change

0.00 0.00%

Volume

Volume 400

Sep 29, 2020, 1:48 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/204944769/composite

Previous close

$ 0.68

$ 0.68

Change

0.00 0.00%

Day low

Day high

$0.68

$0.68

Open
Open: 0.68

52 week low

52 week high

$0.68

$4.00

Open

Market cap

$6.68M

Average volume

2,964

P/E ratio

N/A

Rev. per Employee

N/A

EPS

-0.95

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/mcujf

MarketWatch News on MCUJF

  1. Highlights of rising and falling U.S. stocks

    6:05 p.m. Dec. 5, 2005

    - Michael Baron

  2. Medicure shares rally on positive trial results

    9:46 a.m. Dec. 5, 2005

    - Michael Baron

  3. Medicure's cardioprotective drug granted fast-track status

    9:04 a.m. Sept. 21, 2005

    - Tomi Kilgore

  4. Highlights of rising and falling U.S. stocks

    6:13 p.m. Sept. 14, 2005

    - Michael Baron

  5. Medicure compound meets endpoints in phase II trial

    7:38 a.m. Sept. 14, 2005

    - Michael Baron

  6. Medicure: Will move to Phase III program for MC-4232

    7:33 a.m. Sept. 14, 2005

    - Robert Daniel

  7. Medicure: MC-4232 treats coexisting diabetes, hypertension

    7:33 a.m. Sept. 14, 2005

    - Robert Daniel

  8. Medicure: MC-4232 reaches endpoints in Phase II study

    7:32 a.m. Sept. 14, 2005

    - Robert Daniel

  9. Gold losses lead Canadian markets to lower close

    6:28 p.m. Feb. 18, 2004

    - Susan Lerner

/news/nonmarketwatch/company/us/mcujf

Other News on MCUJF

  1. Medicure Inc. 2020 Q2 - Results - Earnings Call Presentation

    3:06 p.m. Aug. 12, 2020

    - Seeking Alpha

  2. Medicure: How To Destroy A Company

    9:03 a.m. May 16, 2020

    - Seeking Alpha

  3. Medicure Inc. 2019 Q3 - Results - Earnings Call Presentation

    2:13 p.m. Nov. 27, 2019

    - Seeking Alpha

  4. Medicure up 33% on proposed stock buyback plan

    4:30 p.m. Nov. 4, 2019

    - Seeking Alpha

  5. Medicure (MCUJF) Investor Presentation - Slideshow

    10:25 a.m. May 28, 2019

    - Seeking Alpha

  6. Medicure - 3:1 Risk/Reward On A Near-Net/Net

    6:00 a.m. Dec. 7, 2018

    - Seeking Alpha

  7. Medicure sues Gland Pharma for infringement on Aggrastat patent

    6:24 p.m. Nov. 17, 2018

    - Seeking Alpha

  8. Medicure Inc. 2018 Q2 - Results - Earnings Call Slides

    2:26 p.m. Aug. 17, 2018

    - Seeking Alpha

  9. Medicure Inc. 2017 Q3 - Results - Earnings Call Slides

    12:55 p.m. Nov. 24, 2017

    - Seeking Alpha

  10. Loading more headlines...
/news/pressrelease/company/us/mcujf

Press Releases on MCUJF

  1. Medicure Reports Financial Results for Quarter Ended June 30, 2020

    5:00 p.m. Aug. 11, 2020

    - PR Newswire - PRF

  2. Medicure Q2 2020 Results and Conference Call Dates

    12:02 p.m. Aug. 5, 2020

    - PR Newswire - PRF

  3. Health-Care Issues Prove Robust on Final Monday of June

    6:48 p.m. June 30, 2020

    - Baystreet.ca

  4. Medicure Announces Normal Course Issuer Bid

    5:30 p.m. June 29, 2020

    - PR Newswire - PRF

  5. Medicure Announces Normal Course Issuer Bid

    5:30 p.m. June 29, 2020

    - CNW Group

  6. Medicure Reports Financial Results for Quarter Ended March 31, 2020

    5:30 p.m. May 12, 2020

    - PR Newswire - PRF

  7. Medicure Q1 2020 results and conference call dates

    5:00 p.m. May 6, 2020

    - PR Newswire - PRF

  8. Medicure Announces Preliminary Results of Substantial Issuer Bid

    10:00 a.m. Dec. 20, 2019

    - PR Newswire - PRF

  9. Medicure Announces Settlement of Holdback Dispute from Apicore Sale

    7:00 p.m. Dec. 5, 2019

    - PR Newswire - PRF

  10. Medicure Files Patent Infringement Action

    6:30 p.m. Dec. 5, 2019

    - PR Newswire - PRF

  11. Loading more headlines...

Rates »

Link to MarketWatch's Slice.